Abstract: The tendency of an orally-ingestible dietary fiber composition to cause excessive flatulence upon oral administration is reduced considerably by the incorporation therein, in addition to other dietary fiber components, a flatulence-reducing amount of chitosan, or by administering such a flatulence-reducing amount of chitosan concurrently with the other dietary fiber components, illustratively the usual antihyperlipidemic pharmaceutical dietary fiber composition or dietary supplement composition. A preferred dietary fiber composition according to the invention incorporates a plurality of dietary fiber components other than chitosan, preferably acacia gum, pectin, and guar gum, together with a flatulence-reducing amount of chitosan.

Abstract: A method and composition are described for the treatment of mammalian HIV infections including administering an effective subtoxic dosage of melittin (Seq. ID NO:1) to the mammal whereby the growth of HIV infected cells or the replication of the virus in the infected cells of the mammal is inhibited.

Abstract: A procedure for carrying out T cell differentiation of CD34+ stem cells in an in vitro culture of thymic epithelial fragments whereby the differentiated T cells achieve full immunocompetence. The invention also includes the procedure for differentiation of stem cells from HIV seropositive individuals or genetically modified stem cells. The invention broadly relates to the culture of cultured thymic epithelial fragments and provides procedures for verifying true immunocompetence of the resulting T cells and for analyzing the effects of various compounds on the differentiation process. The invention also comprises several novel applications for utilizing the procedure of the invention, including grafting fortified cultured thymic epithelial fragments and infusing immunocompetent T cells into patients with compromised immune systems.

Abstract: The invention relates to a compound selected from those of formula (I): ##STR1## wherein R.sub.1, W and Y are as defined in the description, its geometric and/or optical isomers, and its pharmaceutically-acceptable addition salts with an acid or a base useful as analgesies.

Abstract: The invention relates to novel essentially anhydrous oily bath and shower compositions containing a combination of fatty oil and/or fatty or waxy apolar substance, oil-soluble surfactant, and vesicle-forming lipid and, if desired, a cosmetically- or balneologically-active ingredient. When poured into or simply admixed with water, these formulations immediately and automatically, generate dispersed vesicles or liposomes. They exhibit an immediate as well as a prolonged or depot effect, can be used alone or added to or together with existing bath or shower formulations, and are especially suited for use in connection with or as additives to full, partial, or shower baths.

Abstract: The invention relates to a compound selected from those of formula (I): ##STR1## in which A, R.sub.1, R'.sub.1, R.sub.2, R.sub.3 and n are as defined in the description, and medicinal product containing the same useful for treating a mammal afflicted with a disorder of the melatoninergic system.

Abstract: A compound selected from those of formula: ##STR1## wherein: A--B, n, D and E are as defined in the specification, their racemic mixtures, and their optical isomers, and also the physiologically tolerable salts thereof with appropriate acids.The products of the invention may be used therapeutically.

Abstract: A water-dispersible lipidic hop extract composition, comprising at least 10% by weight of free fatty acid substances derived from hops, is useful to increase the utilization of the hop aroma and flavor components. It may be produced by treatment of an extract of hops with an excess of alkali. The starting hop extract, made conventionally as by extraction with organic solvent or carbon dioxide, preferably has alpha, isoalpha, and beta hop acids removed before treatment with excess alkali. A cosolvent, such as a lower alkanol, polyol, or wetting agent, heat, or high shear may be used to improve mixing of the lipidic organic phase of the hop extract with the excess alkali. The water-dispersible lipidic hop extract imparts an enhanced hop aroma and flavor upon addition to the wort at some point during the brewing process between boiling and the beginning of fermentation. A beer incorporating the dispersible lipidic hop extract has a stronger hop aroma and flavor than beer incorporating the usual hop extract.

Abstract: Compound of formula (I): ##STR1## wherein R, R.sub.1, R.sub.2, R', X and n are as defined in the description, and NEP and ACE inhibitory medicaments containing the same.

Abstract: The present invention discloses compounds of the formula, ##STR1## any mixture thereof, or a pharmaceutically acceptable salt thereof; wherein R, R.sup.3, and R.sup.4 each have the meanings set forth in the specification.The compounds possess valuable pharmaceutical properties as monoamine neurotransmitter, i.e dopamine, serotonin, noradrenalin, reuptake inhibitors.

Abstract: New compounds of formula: ##STR1## wherein: A--D--E, X, n and R are as defined in the description, in racemic form and in the form of optical isomers, and their addition salts with pharmaceutically acceptable acids.Those compounds may be used as medicaments.

Abstract: New substituted 2,2-dimethyl-.omega.-phenoxyalkanoic acids and esters of formula: ##STR1## wherein: X, A, B, R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and Z are as defined in the specification,The corresponding enantiomers and diastereoisomers, and the physiologically tolerable salts thereof with appropriate bases.The products of the invention may be used therapeutically.

Abstract: Method for the preparation of a pharmaceutical composition in the form of microspheres controllably releasing at least one water-soluble active ingredient. The method comprises the steps of dissolving the active ingredient in a suitable quantity of water, emulsifying the aqueous solution containing the active ingredient with a solution of at least a dl-lactide-co-glycolide-type matrix copolymer in chlorinated hydrocarbon also containing a low molecular weight polyactide release-modulating agent, which results in a first microfine and homogeneous emulsion; emulsifying the first emulsion thus obtained in an external aqueous phase containing a surface active agent; and removing and evaporating the solvent to produce microspheres which are recovered after filtering, washing, and drying. The microspheres themselves.

Abstract: Compounds of formula (I): ##STR1## in which: n represents 1 or 2,R.sub.1 represents hydrogen or alkyl, benzyl, acetyl, benzoyl, allyl, pyridinecarbonyl, pyridinemethyl, acylaminoalkyl (optionally substituted), pyridineaminocarbonyl, phthalimidoalkyl, thiochromanyloxyalkyl or (benzodioxanyloxy)alkyl,R.sub.2, R.sub.3 or R.sub.4, which may be identical or different, represent hydrogen or halogen or alkyl, alkoxy, hydroxyl, acetyl, aminocarbonyl, aminomethyl, cyano, nitro, amino, phenyl (which may or may not be substituted), furyl, pyridinyl, thienyl or pyridyl, or alternatively, when they are located on adjacent carbons, R.sub.2 and R.sub.3 form, with the carbon atoms which bear them, a furan or phenyl ring,the isomers thereof and the addition salts thereof with a pharmaceutically acceptable acid, and medicinal products containing the same are useful for the treatment of diseases requiring a ligand to the 5-HT.sub.2C receptors.

Abstract: The invention relates to a compound selected from those of formula (I): ##STR1## in which A, B, X and R.sub.1 are as defined in the description, and medicinal product containing the same useful for treating a disorder of the melatoninergic system.

Abstract: The invention relates to a compound selected from those of formula (I): ##STR1## in which: R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and X are as defined in the description and medicinal product containing the same useful for treating a disorder of the melatoninergic system.

Abstract: A compound selected from those of formula (I): ##STR1## where m is equal to 0 or 1andHet, A, X, R, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and the ring ##STR2## are defined in the description, and a medicinal product comprising the same for treating an inflammatory disorder.

Abstract: The invention relates to a compound selected from these of formula (I): ##STR1## in which R.sub.7, R.sub.8, Y, n and A are as defined in the description, and medicinal product containing the same useful for treating a disorder of the melatoninergic system.

Abstract: A compound of formula (I): ##STR1## in which: R.sub.1 represents an indolyl, naphthyl, tetrahydronaphthyl, thienyl, phenyl, optionally substituted, or (C.sub.3 -C.sub.7)cycloalkyl group,n represents an integer such that 1.ltoreq.n.ltoreq.8,m represents an integer such that 1.ltoreq.m.ltoreq.4,R.sub.2 represents an unsubstituted or substituted benzyl group, an unsubstituted or substituted phenyl group or a linear or branched (C.sub.1 -C.sub.6)alkyl group, its enantiomers, diastereoisomers and epimers as well as its addition salts with a pharmaceutically acceptable acid or base, and medicinal products containing the same are useful as substance P antagonists.

Abstract: A compound which is selected from those of formula (I) : ##STR1## in which A, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are as defined in the description,its optical isomers,and its addition salts thereof with a pharmaceutically-acceptable acid or base,and medicinal products containing the same which are useful for treating a disorder of the melatoninergic system.